These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

145 related items for PubMed ID: 16507487

  • 21. Evidence for TIMP-1 protection against P. aeruginosa-induced corneal ulceration and perforation.
    Kernacki KA, Barrett R, Hazlett LD.
    Invest Ophthalmol Vis Sci; 1999 Dec; 40(13):3168-76. PubMed ID: 10586939
    [Abstract] [Full Text] [Related]

  • 22. Improved bacterial clearance and decreased mortality can be induced by LPS tolerance and is not dependent upon IFN-gamma.
    Murphey ED, Fang G, Varma TK, Sherwood ER.
    Shock; 2007 Mar; 27(3):289-95. PubMed ID: 17304110
    [Abstract] [Full Text] [Related]

  • 23. ST2 is essential for Th2 responsiveness and resistance to pseudomonas aeruginosa keratitis.
    Huang X, Du W, Barrett RP, Hazlett LD.
    Invest Ophthalmol Vis Sci; 2007 Oct; 48(10):4626-33. PubMed ID: 17898286
    [Abstract] [Full Text] [Related]

  • 24. The role of STAT1/IRF-1 on synergistic ROS production and loss of mitochondrial transmembrane potential during hepatic cell death induced by LPS/d-GalN.
    Lee HJ, Oh YK, Rhee M, Lim JY, Hwang JY, Park YS, Kwon Y, Choi KH, Jo I, Park SI, Gao B, Kim WH.
    J Mol Biol; 2007 Jun 15; 369(4):967-84. PubMed ID: 17475277
    [Abstract] [Full Text] [Related]

  • 25. Complementary roles of tumor necrosis factor alpha and interferon gamma in inducible microglial nitric oxide generation.
    Mir M, Tolosa L, Asensio VJ, Lladó J, Olmos G.
    J Neuroimmunol; 2008 Nov 15; 204(1-2):101-9. PubMed ID: 18703234
    [Abstract] [Full Text] [Related]

  • 26. The role of VIP in cornea.
    Jiang X, McClellan SA, Barrett RP, Zhang Y, Foldenauer ME, Hazlett LD.
    Invest Ophthalmol Vis Sci; 2012 Nov 07; 53(12):7560-6. PubMed ID: 23074208
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Aging and PMN response to P. aeruginosa infection.
    Kernacki KA, Barrett RP, McClellan SA, Hazlett LD.
    Invest Ophthalmol Vis Sci; 2000 Sep 07; 41(10):3019-25. PubMed ID: 10967059
    [Abstract] [Full Text] [Related]

  • 30. Nona-D-arginine amide for prophylaxis and treatment of experimental Pseudomonas aeruginosa keratitis.
    Karicherla P, Hobden JA.
    Curr Eye Res; 2010 Mar 07; 35(3):220-4. PubMed ID: 20373880
    [Abstract] [Full Text] [Related]

  • 31. A novel murine model for contact lens wear reveals clandestine IL-1R dependent corneal parainflammation and susceptibility to microbial keratitis upon inoculation with Pseudomonas aeruginosa.
    Metruccio MME, Wan SJ, Horneman H, Kroken AR, Sullivan AB, Truong TN, Mun JJ, Tam CKP, Frith R, Welsh L, George MD, Morris CA, Evans DJ, Fleiszig SMJ.
    Ocul Surf; 2019 Jan 07; 17(1):119-133. PubMed ID: 30439473
    [Abstract] [Full Text] [Related]

  • 32. A protective role for IL-6 in staphylococcal microbial keratitis.
    Hume EB, Cole N, Garthwaite LL, Khan S, Willcox MD.
    Invest Ophthalmol Vis Sci; 2006 Nov 07; 47(11):4926-30. PubMed ID: 17065508
    [Abstract] [Full Text] [Related]

  • 33. Nona-D-arginine therapy for Pseudomonas aeruginosa keratitis.
    Karicherla P, Hobden JA.
    Invest Ophthalmol Vis Sci; 2009 Jan 07; 50(1):256-62. PubMed ID: 18775859
    [Abstract] [Full Text] [Related]

  • 34. IL-18 contributes to host resistance against infection with Pseudomonas aeruginosa through induction of IFN-gamma production.
    Huang X, McClellan SA, Barrett RP, Hazlett LD.
    J Immunol; 2002 Jun 01; 168(11):5756-63. PubMed ID: 12023376
    [Abstract] [Full Text] [Related]

  • 35. High-mobility group box 1: a novel target for treatment of Pseudomonas aeruginosa keratitis.
    McClellan S, Jiang X, Barrett R, Hazlett LD.
    J Immunol; 2015 Feb 15; 194(4):1776-87. PubMed ID: 25589066
    [Abstract] [Full Text] [Related]

  • 36. Effects of VIP on corneal reconstitution and homeostasis following Pseudomonas aeruginosa induced keratitis.
    Berger EA, Vistisen KS, Barrett RP, Hazlett LD.
    Invest Ophthalmol Vis Sci; 2012 Nov 01; 53(12):7432-9. PubMed ID: 23036997
    [Abstract] [Full Text] [Related]

  • 37. Secretory IgA inhibits Pseudomonas aeruginosa binding to cornea and protects against keratitis.
    Masinick SA, Montgomery CP, Montgomery PC, Hazlett LD.
    Invest Ophthalmol Vis Sci; 1997 Apr 01; 38(5):910-8. PubMed ID: 9112987
    [Abstract] [Full Text] [Related]

  • 38. Degradation of uniquely glycosylated secretory immunoglobulin a in tears from patients with Pseudomonas aeruginosa keratitis.
    Lomholt JA, Kilian M.
    Invest Ophthalmol Vis Sci; 2008 Nov 01; 49(11):4939-44. PubMed ID: 18757515
    [Abstract] [Full Text] [Related]

  • 39. Surfactant protein D in Pseudomonas aeruginosa keratitis.
    McCormick CC, Hobden JA, Balzli CL, Reed JM, Caballero AR, Denard BS, Tang A, O'Callaghan RJ.
    Ocul Immunol Inflamm; 2007 Nov 01; 15(5):371-9. PubMed ID: 17972221
    [Abstract] [Full Text] [Related]

  • 40. Caspase-1 inhibitor reduces severity of pseudomonas aeruginosa keratitis in mice.
    Thakur A, Barrett RP, Hobden JA, Hazlett LD.
    Invest Ophthalmol Vis Sci; 2004 Sep 01; 45(9):3177-84. PubMed ID: 15326138
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.